Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.
To evaluate the efficacy and safety of routine P-CAB use in patients with coronary artery disease who underwent PCI and maintain DAPT, as compared to guideline-directed proton pump inhibitor (PPI) usage.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Routine use of P-CAB | All-comer patients with P-CAB |
| |
| Guideline-directed GI protection strategy | Use of PPI or not according to GI bleeding risk |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Routine use of P-CAB on DAPT | Drug | This group received P-CAB with DAPT after PCI. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Major GI bleeding | Major GI bleeding requiring transfusion | at 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Clinically relevant GI bleeding | Clinically relevant GI bleeding | At 1 year |
| Major adverse cardiac event | A composite of cardiovascular death, myocardial infarction, and repeat revascularization |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients with coronary artery disease who underwent PCI
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ki Hong Choi, MD, PhD | Contact | 82-2-3410-3419 | cardiokh@gmail.com | |
| Danbee Kang, PhD | Contact | 82-2-2148-7197 | dbee.kang@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| KI HONG CHOI, MD, PhD | Samsung Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Samsung Medical Center | Recruiting | Seoul | 06351 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Guideline Directed Medical Therapy |
| Drug |
This group received PPI or not with DAPT after PCI according to GI bleeding risk. |
|
| At 1 year |
| Cardiovascular death | Cardiovascular death | At 1 year |
| Myocardial infarction | Myocardial infarction | At 1 year |
| Repeat revascularization | Repeat revascularization | At 1 year |
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided